Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity
Clinical & Translational Immunology (2019) - Comment
pubmed: 31572609  doi: 10.1002/cti2.1081  issn: 2050-0068 

William C. Dougall, Amelia Roman Aguilera, Mark J. Smyth